← Back to Clinical Trials
Recruiting NCT06808451

NCT06808451 Diagnosis and Treatment of Urinary Tract Infection Using DNA Polymerase Chain Reaction Versus Urine Culture

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06808451
Status Recruiting
Phase
Sponsor University Hospitals Cleveland Medical Center
Condition Urinary Tract Infections
Study Type INTERVENTIONAL
Enrollment 136 participants
Start Date 2025-10-22
Primary Completion 2026-09-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
DNA PCRUrine Culture

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 136 participants in total. It began in 2025-10-22 with a primary completion date of 2026-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Adults 18 years or older with urinary tract infection (UTI) symptoms. Participants will be assigned to either the urine culture group or the DNA PCR study group by randomization. At time of enrollment in the study they will be also asked to fill out two questionnaires. If prescribed antibiotics for treatment of a UTI, participants will then be called the day after they are scheduled to stop their antibiotics. Participants will be asked to fill out questionnaires the day after finishing antibiotics. Participants will be enrolled in the study for a maximum of 21 days.

Eligibility Criteria

Inclusion Criteria: * Adult men and women 18 years and older * Presenting to clinic with symptoms of UTI or cystitis * Patients with Medicare and Medicaid insurance Exclusion Criteria: * Urinary diversion of any type * Chronic indwelling urinary catheter * Diagnosed UTI within the previous 21 days * Antibiotic therapy within the previous 21 days * Use of phenazopyridine within the previous 21 days * Commercial insurance * Non-English speaking * Pregnant patients

Contact & Investigator

Central Contact

Diana N Mitchell, MD, MBA, BSN

✉ diana.mitchell@uhhospitals.org

📞 216-844-1000

Principal Investigator

David Sheyn, MD

PRINCIPAL INVESTIGATOR

University Hospitals

Frequently Asked Questions

Who can join the NCT06808451 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Urinary Tract Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06808451 currently recruiting?

Yes, NCT06808451 is actively recruiting participants. Contact the research team at diana.mitchell@uhhospitals.org for enrollment information.

Where is the NCT06808451 trial being conducted?

This trial is being conducted at Cleveland, United States.

Who is sponsoring the NCT06808451 clinical trial?

NCT06808451 is sponsored by University Hospitals Cleveland Medical Center. The principal investigator is David Sheyn, MD at University Hospitals. The trial plans to enroll 136 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology